ESTEVE CDMO expands manufacturing capacity in China with $80 million investment
ESTEVE CDMO has opened a new production facility in China as part of an $80 million capital investment to boost its global manufacturing footprint.
Pharmaceutical contract development and manufacturing organization (CDMO) ESTEVE CDMO has completed an $80 million investment project aimed at expanding its production capabilities in China. The project features a new facility designed to increase reaction capacity and output volume.
The site comprises three distinct manufacturing workshops, providing additional infrastructure for complex drug substance production. The investment is intended to address the rising demand for manufacturing services within the pharmaceutical sector and improve ESTEVE CDMO's capacity to serve international markets.
By scaling operations in China, the company aims to solidify its position in the global supply chain. This expansion marks a shift in the company's manufacturing strategy, focusing on increased production capacity to accommodate the requirements of its global client base.